NCT05121142已完成1 期
Pharmacokinetics and Pharmacodynamic Study of Ruxolitinib for the Management of Acute and Chronic Graft Versus Host Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Cmax of ruxolitinib in existing patients with chronic GVHD (Arm 1)
研究概览
简要总结
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT. Both acute GVHD and chronic GVHD are leading causes of non-relapse morbidity and mortality. Patients with solid organ transplants may participate in this study as well because these patients occasionally develop acute GVHD, which is biologically similar to acute GVHD after an HSCT.
Acute graft versus host disease usually occurs within the first 100 days of transplant and can involve the skin, gut, or liver. Chronic graft versus host disease usually occurs after the first 100 days of transplant and can involve skin, eyes, mouth, joints, liver, intestines commonly. These two diseases are different, but both happen due to the imbalance of the donor immune system in the host.
The purpose of this research is to learn more about ruxolitinib as a treatment for both acute and chronic GVHD. Specifically, the investigators would like to learn more about the pharmacokinetics (PK - the process of absorption, distribution, metabolism, and elimination from the body - meaning how the drug moves through the body) and the pharmacodynamics (PD - the body's biological response to the drug) of ruxolitinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Established diagnosis of chronic GVHD (all grades eligible)
- •Currently on treatment with ruxolitinib for chronic GVHD for a minimum of 3 weeks
- •No changes in doses of ruxolitinib or concurrent azoles (if present) one week prior to obtaining ruxolitinib levels
- •Ages eligible for enrollment (0-≤18 years at time of enrollment)
排除标准
- •Clinical presentation resembling overlap syndrome with both acute and chronic GVHD features
- •Inclusion Criteria:
- •Ages <12 years status post allogeneic hematopoietic stem cell transplant or solid organ transplant
- •Any underlying diagnoses, preparative regimen, stem cell source or acute GVHD prophylaxis are eligible
- •Diagnosis of acute GVHD which is refractory to steroids (defined as lack of improvement to 2 mg/kg/day of methylprednisolone or bioequivalent oral steroids, for 7 days or progression of acute GVHD within 72 hours at 2 mg/kg/day of Methylprednisolone or bioequivalent oral doses)
- •Able to take enteral medications
- •Clinically diagnosed Grades II to IV acute GVHD as per modified Glucksberg criteria occurring after allogeneic HSCT requiring systemic immune suppressive therapy. Biopsy of involved organs with acute GVHD is encouraged but not required for study enrollment.
- •Blood counts at decision to initiate ruxolitinib: absolute neutrophil count (ANC) > 1000/mm3* AND platelets ≥ 20,000/mm3 (*Use of growth factor supplementation and transfusion support is allowed to achieve these above defined hematological parameters)
- •Estimated GFR by cystatin C of >30 mL/min
- •Prior systemic treatments for acute GVHD are allowed. Once ruxolitinib is initiated, no further doses of these agents will be allowed.
- •Calcineurin inhibitors are allowed throughout the duration of study and may be discontinued per treating physician discretion. Additionally dose adjustments to maintain target blood levels of calcineurin inhibitors may proceed per routine clinical practice.
- •Exclusion Criteria:
- •Clinical presentation resembling de novo chronic GVHD or GVHD overlap syndrome with both acute and chronic GVHD features
- •Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- •Evidence of uncontrolled viral reactivation (Adenovirus, CMV, EBV, BK virus). If patients are on appropriate antiviral therapy or have received virus specific T-cells (either donor derived or third-party) then the viral reactivation is not considered uncontrolled.
- •Presence of relapsed primary malignancy.
- •Inclusion Criteria:
- •0-≤18 years of age are eligible
- •Any underlying diagnosis, preparative regimen, stem cell source or prior acute GVHD prophylaxis are eligible
- •Diagnosis of chronic GVHD as per 2014 NIH consensus criteria (any organ involvement is eligible)
- •Any GVHD global severity is eligible
- •Patients may have received methylprednisolone or oral bioequivalent steroids at a dose of 1 mg/kg/day (or greater) for up to 28 days prior to enrollment but may be enrolled anytime between diagnosis of chronic GVHD and day 28 of systemic steroids
- •Concurrent local therapies ( including but not limited to topical steroids, topical calcipotriene, ocular drops such as restasis, autologous serum eye drops, artificial tears, triamcinolone ointment for vulvar GVHD, Fluticasone Azithromycin and Singulair) are allowed at anytime while on ruxolitinib . Additional therapies may also be considered with PI review and approval
- •As children may not meet criteria for lung GVHD due to inability to perform PFTs we will establish the diagnosis of lung GVHD for children as defined by any of the following criteria listed below. However, the participants do not need to have lung involvement to be eligible to receive ruxolitinib.
- •>10% decrease in FEV1 or FVC from baseline or 25% of FEF 25-75
- •Active GVHD in another organ system + pulmonary symptoms (Tachypnea without wheezing, new oxygen requirement, cough)
- •Increased R5 by 50% by Impulse oscillometry
- •Air trapping on high resolution CT scan, small airway thickening, or bronchiectasis in the absence of infection
- •Negative urine or serum pregnancy test for females of childbearing age
- •Estimated GFR by cystatin C > 30 mL/min
- •Able to take enteral medications
- •Exclusion Criteria:
- •Clinical presentation resembling overlap syndrome with both acute and chronic GVHD features
- •Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- •Evidence of uncontrolled viral reactivation (Adenovirus, CMV, EBV, BK virus). If patients are on appropriate antiviral therapy or have received virus specific T-cells (either donor derived or third-party) then the viral reactivation is not considered uncontrolled.
- •Presence of relapsed primary malignancy.
研究组 & 干预措施
Arm 2: Acute GVHD ages 0-<12 years
Experimental
Participants with acute GVHD will receive ruxolitinib on this arm.
干预措施: Ruxolitinib (Drug)
Arm 3: New onset chronic GVHD ages 0-≤18 years
Experimental
Participants with new onset chronic GVHD will receive ruxolitinib on this arm.
干预措施: Ruxolitinib (Drug)
结局指标
主要结局
Cmax of ruxolitinib in existing patients with chronic GVHD (Arm 1)
时间窗: 1 week
Maximum Plasma Concentration of ruxolitinib
Cmax of ruxolitinib in patients with acute GVHD (Arm 2)
时间窗: 30 days
Maximum Plasma Concentration of ruxolitinib
Cmax of ruxolitinib in patients with new onset chronic GVHD (Arm 3)
时间窗: 6 months
Maximum Plasma Concentration of ruxolitinib
To measure phosphorylation of STAT5 on lymphocytes as a functional measure of JAK inhibition (Arms 1, 2, and 3)
时间窗: Approximately 2 hours after the ruxolitinib dose
A blood sample will be collected at the specified time point and pharmacodynamics will be measured by PSTAT5
次要结局
- Number of participants with overall survival (Arm 3)(6 months after ruxolitinib initiation)
- Number of participants with complete response to ruxolitinib (Arm 2)(30 days after ruxolitinib initiation)
- Number of participants with partial response to ruxolitinib (Arm 2)(30 days after ruxolitinib initiation)
- Incidence of infections (Arm 1)(through study completion, average of 7 days)
- Number of participants with no response to ruxolitinib (Arm 2)(30 days after ruxolitinib initiation)
- Number of participants with response to ruxolitinib (Arm 3)(6 months after ruxolitinib initiation)
- Number of participants with relapse free survival at 6 months (Arm 1)(6 months after ruxolitinib initiation)
- Incidence of known side effects (Arm 1)(through study completion, average of 7 days)
- Incidence of known side effects (Arm 2)(30 days after ruxolitinib initiation)
- Incidence of known side effects (Arm 3)(6 months after ruxolitinib initiation)
- Number of participants with relapse free survival at 6 months (Arm 3)(6 months after ruxolitinib initiation)
- Incidence of infections (Arm 3)(6 months after ruxolitinib initiation)
- Incidence of infections (Arm 2)(30 days after ruxolitinib initiation)
- Incidence of unknown side effects (Arm 1)(through study completion, average of 7 days)
- Incidence of unknown side effects (Arm 2)(30 days after ruxolitinib initiation)
- Incidence of unknown side effects (Arm 3)(6 months after ruxolitinib initiation)
- Number of participants who were weaned off steroids (Arm 2)(30 days after ruxolitinib initiation)
- Number of participants who were weaned off steroids (Arm 3)(6 months after ruxolitinib initiation)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Upfront Ruxolitinib for Chronic Graft-vs-host DiseaseNCT06695507Children's Hospital Medical Center, Cincinnati1
已完成
2 期
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)Chronic Graft-versus-host DiseaseNCT01161628Northside Hospital, Inc.25
进行中（未招募）
1 期
Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trialprimary myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005210-28-DEniversity Medical Center Hamburg-Eppendorf155
招募中
2 期
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)Haemophagocytic LymphohistiocytosisNCT05762640Assistance Publique - Hôpitaux de Paris20
已完成
2 期
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationGraft Versus Host DiseaseHematologic MalignanciesNCT00146614Dana-Farber Cancer Institute105